We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 233

Novartis AG v. Ezra Ventures LLC
  • Knobbe Martens
  • USA
  • December 10 2018

Novartis owns at least two patents covering the multiple sclerosis drug Gilenya, the ‘229 patent and the ‘565 patent. The ‘229 patent, a pre-URAA


Legislative Developments for NJ Cannabis Insider
  • Windels Marx Lane & Mittendorf LLP
  • USA
  • December 6 2018

Industrial hemp production, however, is quietly emerging as the biggest development in the nascent cannabis industry


Cannabis: what's new for the 6000 year old medicine?
  • Taylor Wessing
  • United Kingdom
  • November 8 2018

Recent changes to the rules in the UK have raised some interesting possibilities and questions


Missouri’s 2018 medical cannabis initiatives: Part 1 - The basics
  • Thompson Coburn LLP
  • USA
  • October 25 2018

Three initiatives on Missouri’s November 6, 2018, ballot seek to make medical marijuana or medical cannabis legal under Missouri state law. This


“Blocking Patent” Deterrence Effect May Discount Secondary Considerations for Follow-On Patents
  • McDermott Will & Emery
  • USA
  • October 24 2018

The US Court of Appeals for the Federal Circuit affirmed a district court's obviousness determination, finding that a patentee's exclusive


PTAB Upholds GILENYA Method of Treatment Patent, Prompting New ANDA Litigation
  • Jones Day
  • USA
  • July 30 2018

In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not


Australian Federal Budget 2018-19: Heathcare Overview
  • Baker McKenzie
  • USA
  • May 9 2018

Last night, the Treasurer delivered the Australian Federal Budget for 2018-19. Below is a high level overview of the proposed changes (subject to


Mintz Levin Health Care Qui Tam Update
  • Mintz
  • USA
  • March 31 2018

We identified 56 health care related qui tam cases that were unsealed in October and November 2017. The intervention rate for those unsealed cases


Additional Discovery of Clinical Trial Data in Inter Partes Review
  • Baker & Hostetler LLP
  • USA
  • March 30 2018

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase


Massachusetts Health Care Update: Senate Bill, Medication Switching, and Opioids
  • Mintz
  • USA
  • November 20 2017

Massachusetts policymakers continue to debate health care reform proposals with important implications for industry stakeholders. This month the